Clinical Trials Logo

Liver Steatosis clinical trials

View clinical trials related to Liver Steatosis.

Filter by:

NCT ID: NCT03386890 Recruiting - Liver Fibrosis Clinical Trials

Clinical Application of Non-invasive Assessment for Staging Liver Steatosis and Liver Fibrosis

Start date: December 2015
Phase: N/A
Study type: Observational

Nowadays, the morbidity of Nonalcoholic fatty liver disease (NAFLD) show ascending trend year by year, which has become an important public health problem in China. As NAFLD can progress to Non-alcoholic steatohepatitis (NASH), cirrhosis and Hepatocarcinoma, the identification and quantitative evaluation of liver steatosis and its dynamic changes are crucial. While liver biopsy is still the gold standard in the diagnosis of NAFLD, its application is limited because of the invasive procedure.The Transient Elastography(TE) combined with the Controlled Attenuation Parameter(CAP) is a new non-invasive diagnostic method for fatty liver and liver fibrosis. In order to evaluate the diagnostic value of non-invasive assessment for the degree of liver steatosis and staging liver fibrosis, this non-invasive method will be assessed by the golden standard of liver biopsy among 400 NAFLD patients.The treatment protocols will be decided by doctor and patient both (treatment protocols and medicine are not required). Blood routine, blood biochemistry, abdominal ultrasound and Transient Elastography(TE) combined with the Controlled Attenuation Parameter(CAP) are detected during the follow-up.

NCT ID: NCT02798861 Completed - Liver Disease Clinical Trials

Controlled Attenuation Parameter (CAP) in Liver Allografts

Start date: September 7, 2016
Phase:
Study type: Observational

The primary aim is to determine the accuracy of CAP in the quantification of liver steatosis using liver biopsies as reference. Secondarily, investigators will correlate transient elastography (TE) and CAP results, analyze possible associations between CAP/TE and post-liver transplant (LT) clinical outcomes, and evaluate the change in CAP after LT. The study aims to include as many donors as needed to achieve at least 120 transplanted liver allografts.

NCT ID: NCT02575625 Recruiting - Liver Steatosis Clinical Trials

Fibroscan® Medical Device, Assessment for Non Invasive Diagnosis of Liver Steatosis

TRANSTEATOSE
Start date: April 2013
Phase: N/A
Study type: Interventional

Hypothesis of this study is the existence of a relation between parameters measured by FibroScan® FS 502 according to our non invasive method and liver steatosis condition. This proof of concept validation is made up of two steps: - Step 1: feasibility study of the method on 10 healthy volunteers - Step 2: diagnosis study on 50 healthy volunteers (25 between 18-30 years-old and 25 between 40-65 years-old) and on 25 patients whom cares including an liver biopsy et whom the histological answer is clean steatosis (NAFLD). Experimental procedures consist in: - Fibroscan measure, preceded by tracking ultrasonography. - liver MRI (for substudy about MRI comparison, in step 2) - a blood test for biological assessment of liver functions

NCT ID: NCT02456766 Recruiting - Fatty Liver Clinical Trials

Comparison of Acoustic Attenuation Parameter Using FibroTouch With Liver Biopsy for Diagnosis of Hepatic Steatosis

Start date: June 2014
Phase: N/A
Study type: Observational

This will be a multi-center, prospective, controlled study. It is expected that about 240 subjects from 10 study centers will be enrolled, and 224 effective subjects will be statistically analyzed in the end, in which 56 effective subjects with stage F0 (25%), 56 effective subjects with stage F1 (25%), 56 effective subjects with stage F2 (25%), 56 effective subjects with stage F3 (25%). By comparison of the result of FibroTouch examination with that of liver biopsy, their specificities, sensitivities and accuracies for diagnosis of liver steatosis will be identified. The patients with liver diseases who need to have a liver biopsy in hospital and meet all of the inclusion criteria and none of the exclusion criteria, may participate in this study. Within two weeks of FibroTouch examination, subjects are required to have qualified histological specimens of liver biopsy for comparation.

NCT ID: NCT02337894 Not yet recruiting - Insulin Resistance Clinical Trials

Effects of Amino Acid Supplementation on Liver Lipid Content and Protein Metabolism in Obese Children

Start date: January 30, 2022
Phase: N/A
Study type: Interventional

The purpose of this study is to assess the effect of an eight-week dietary supplementation with essential amino acids plus arginine on liver and plasma lipid content, whole-body fat oxidation, whole-body insulin sensitivity, whole body protein metabolism, and body composition in obese pre-pubertal children.

NCT ID: NCT02307344 Not yet recruiting - Clinical trials for Nonalcoholic Steatohepatitis

Effect of Nigella Sativa on Nonalcoholic Steatohepatitis and Steatosis

NASH NAFLD
Start date: January 2015
Phase: N/A
Study type: Interventional

The investigators hypothesize that Nigella Sativa will have an effect on Nonalcoholic Steatohepatitis and Liver Steatosis by enhancing lipophagy in the liver tissue.

NCT ID: NCT01758770 Completed - Obesity Clinical Trials

China Action on Spine and Hip Status

CASH
Start date: October 2012
Phase: N/A
Study type: Observational

1. To determine the prevalences of osteoporotic fracture in elderly Chinese population. 2. To determine the prevalences of osteoporosis in elderly Chinese population using QCT BMD measurement. 3. To investigate the difference in the prevalences of osteoporosis between cities and urban-rural area in China. 4. To investigate the association of body composition with osteoporosis 5. To investigate the prevalence of liver steatosis in China 6. To investigate the application of QCT fat measurement